Molecular Cancer · 2010 · 16 citations · 38 references
Life SciencesMolecular BiologyPharmacologyDrug DiscoveryMolecular Cell BiologyStructural BiologyLigand BindingProtein-protein Interaction ModelingAnimal Disease ModelsComputational ScreeningJak Inhibitor TherapyJak InhibitorsKinase Domain MutationsLead Compound ScreeningStructure-based ScreeningTherapeutic Target Identification
BACKGROUND: Human or animals lacking either JAK3 or the common gamma chain (gammac) expression display severe combined immunodeficiency disease, indicating the crucial role of JAK3 in T-cell development and the homeostasis of the immune system. JAK3 has also been suggested to contribute to the pathogenesis of tumorigenesis. Recent studies identified activating JAK3 mutations in patients with various hematopoietic malignancies, including acute megakaryoblastic leukemia. Importantly, functional analyses of some of those JAK3 mutations have been shown to cause lethal hematopoietic malignancies in animal models. These observations make JAK3 an ideal therapeutic target for the treatment of various human diseases. To identify novel small molecule inhibitors of JAK3, we performed structure-based virtual screen using the 3D structure of JAK3 kinase domain and the NCI diversity set of compounds. RESULTS: We identified NSC114792 as a lead compound. This compound directly blocked the catalytic activity of JAK3 but not that of other JAK family members in vitro. In addition, treatment of 32D/IL-2Rbeta cells with the compound led to a block in IL-2-dependent activation of JAK3/STAT5 but not IL-3-dependent activation of JAK2/STAT5. Consistent with the specificity of NSC114792 for JAK3, it selectively inhibited persistently-activated JAK3, but failed to affect the activity of other JAK family members and other oncogenic kinases in various cancer cell lines. Finally, we showed that NSC114792 decreases cell viability by inducing apoptosis through down-regulating anti-apoptotic gene expression only in cancer cells harboring persistently-active JAK3. CONCLUSIONS: NSC114792 is a lead compound that selectively inhibits JAK3 activity. Therefore, our study suggests that this small molecule inhibitor of JAK3 can be used as a starting point to develop a new class of drugs targeting JAK3 activity, and may have therapeutic potential in various diseases that are caused by aberrant JAK3 activity.
38
The Amber biomolecular simulation programs
David A. Case, Thomas E. Cheatham, Tom Darden et al. · Journal of Computational Chemistry · 2005 · 9.6K citations · Full text
Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor
Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 670 citations · Full text
Medicine, Immunology, Pharmacology +17
Defective Lymphoid Development in Mice Lacking Jak3
Tetsuya Nosaka, Jan M. A. van Deursen, Ralph A. Tripp et al. · Science · 1995 · 649 citations
Life Sciences, Genetics, Immunology +15
Michelle A. Blaskovich, Jiazhi Sun, Alan Cantor et al. · PubMed · 2003 · 569 citations
Medicine, Oncology, Pharmacology +15